For instance, autoantibodies against tau protein can reduce pathology and functional decline in animal models of tauopathies and may be beneficial in Alzheimer's disease and Parkinson's disease. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.